Total Payments
$6,881
2024 Payments
$464.97
Companies
17
Transactions
246
Medicare Patients
647
Medicare Billing
$66,299
Payment Breakdown by Category
Food & Beverage$6,638 (96.5%)
Education$242.61 (3.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,638 | 240 | 96.5% |
| Education | $242.61 | 6 | 3.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $2,440 | 63 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $1,077 | 53 | $0 (2020) |
| Astellas Pharma US Inc | $1,055 | 45 | $0 (2022) |
| Gilead Sciences, Inc. | $962.56 | 38 | $0 (2024) |
| Allergan, Inc. | $349.23 | 17 | $0 (2020) |
| ABBVIE INC. | $183.96 | 5 | $0 (2022) |
| Insmed, Inc. | $160.89 | 5 | $0 (2020) |
| Melinta Therapeutics, LLC | $158.85 | 3 | $0 (2022) |
| The Medicines Company | $118.68 | 6 | $0 (2017) |
| Shionogi Inc | $116.83 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $464.97 | 4 | ViiV Healthcare Company ($242.03) |
| 2023 | $351.39 | 3 | ViiV Healthcare Company ($227.92) |
| 2022 | $264.04 | 8 | ViiV Healthcare Company ($141.75) |
| 2021 | $616.31 | 8 | ViiV Healthcare Company ($327.21) |
| 2020 | $549.36 | 20 | ViiV Healthcare Company ($259.28) |
| 2019 | $1,707 | 71 | ViiV Healthcare Company ($301.91) |
| 2018 | $1,556 | 68 | Merck Sharp & Dohme Corporation ($492.05) |
| 2017 | $1,371 | 64 | ViiV Healthcare Company ($488.32) |
All Payment Transactions
246 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/24/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $99.52 | General |
| Category: HIV | ||||||
| 10/21/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $117.03 | General |
| Category: HIV | ||||||
| 07/25/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $123.42 | General |
| Category: HIV | ||||||
| 03/28/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 12/06/2023 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $124.99 | General |
| 09/07/2023 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $102.93 | General |
| 08/17/2023 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $123.47 | General |
| Category: HIV | ||||||
| 11/02/2022 | Melinta Therapeutics, LLC | Vabomere (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: ANTIBIOTICS | ||||||
| 07/12/2022 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $59.76 | General |
| 05/18/2022 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: Infectious Diseases | ||||||
| 04/13/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.76 | General |
| 04/12/2022 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $81.99 | General |
| 03/30/2022 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $24.45 | General |
| Category: Infectious Diseases | ||||||
| 03/02/2022 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $19.47 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/21/2022 | Theratechnologies Inc. | EGRIFTA (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: HIV | ||||||
| 12/16/2021 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $99.39 | General |
| 11/03/2021 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Orbactiv | Food and Beverage | In-kind items and services | $109.26 | General |
| Category: ANTIBIOTICS | ||||||
| 08/19/2021 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $63.31 | General |
| 07/21/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.02 | General |
| 06/23/2021 | Astellas Pharma US Inc | — | Education | In-kind items and services | $39.99 | General |
| 06/03/2021 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $116.83 | General |
| Category: Infections and Infectious Diseases | ||||||
| 04/14/2021 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $89.48 | General |
| 03/23/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $75.03 | General |
| Category: HIV | ||||||
| 11/10/2020 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $107.53 | General |
| Category: HIV | ||||||
| 08/11/2020 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $95.60 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 168 | 196 | $38,434 | $16,887 |
| 2022 | 6 | 179 | 219 | $44,307 | $19,612 |
| 2021 | 6 | 141 | 165 | $31,584 | $14,369 |
| 2020 | 6 | 159 | 229 | $32,768 | $15,431 |
Total Patients
647
Total Services
809
Medicare Billing
$66,299
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 70 | 79 | $18,012 | $7,944 | 44.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 43 | 51 | $6,352 | $3,161 | 49.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 16 | 22 | $4,840 | $2,076 | 42.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 27 | 32 | $4,960 | $2,075 | 41.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $4,270 | $1,631 | 38.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 35 | 38 | $12,862 | $5,851 | 45.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 39 | 41 | $9,412 | $4,288 | 45.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 46 | 64 | $7,808 | $3,546 | 45.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 26 | 29 | $6,380 | $2,705 | 42.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 28 | $4,900 | $2,226 | 45.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 14 | 19 | $2,945 | $996.28 | 33.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 41 | 41 | $9,430 | $4,365 | 46.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 27 | 31 | $6,369 | $2,666 | 41.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 33 | 43 | $5,236 | $2,423 | 46.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $4,398 | $2,041 | 46.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 15 | 23 | $4,013 | $1,864 | 46.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 12 | 14 | $2,138 | $1,011 | 47.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 44 | 92 | $10,039 | $5,286 | 52.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 34 | 34 | $7,820 | $3,614 | 46.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 29 | $4,457 | $2,390 | 53.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 23 | 23 | $3,851 | $1,647 | 42.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 25 | 27 | $3,193 | $1,265 | 39.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 21 | 24 | $3,408 | $1,228 | 36.0% |
About Dr. Christopher Crist, M.D
Dr. Christopher Crist, M.D is a Infectious Disease healthcare provider based in Lubbock, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/24/2011. The National Provider Identifier (NPI) number assigned to this provider is 1598051856.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Crist, M.D has received a total of $6,881 in payments from pharmaceutical and medical device companies, with $464.97 received in 2024. These payments were reported across 246 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($6,638).
As a Medicare-enrolled provider, Crist has provided services to 647 Medicare beneficiaries, totaling 809 services with total Medicare billing of $66,299. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Lubbock, TX
- Active Since 06/24/2011
- Last Updated 01/11/2022
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1598051856
Products in Payments
- TRIUMEQ (Drug) $559.18
- ZERBAXA (Drug) $521.49
- ISENTRESS (Drug) $477.72
- Biktarvy (Drug) $441.29
- CRESEMBA (Drug) $354.48
- DOVATO (Drug) $340.28
- JULUCA (Drug) $317.60
- AVYCAZ (Drug) $291.44
- Cresemba (Drug) $272.96
- CABENUVA (Biological) $192.06
- TIVICAY (Drug) $152.77
- Mavyret (Drug) $140.59
- MYCAMINE (Drug) $122.17
- Fetroja (Drug) $116.83
- Kimyrsa (Drug) $109.26
- XPERT (Device) $83.61
- Arikayce (Drug) $80.03
- TEFLARO (Drug) $77.26
- MINOCIN IV (Drug) $52.27
- VABOMERE (Drug) $51.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Lubbock
Richard Winn, Md, MD
Infectious Disease — Payments: $43,731
Infectious Disease $43,731
Dr. Dennis Duriex, M.d, M.D
Infectious Disease — Payments: $8,967
Infectious Disease $8,967
Prakash Shrestha, Md, MD
Infectious Disease — Payments: $5,058
Infectious Disease $5,058
Dr. Lawrence Martinelli, M.d, M.D
Infectious Disease — Payments: $28.71
Infectious Disease $28.71